Siddhartha P. Sarma

Siddhartha P. Sarma

Auto-generated profile, based on publicly available information

Siddhartha P. Sarma

Molecular Biophysics Unit, Indian Institute of Science, Bengaluru, Karnataka 560012, India

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
DNDeepesh Nagarajan
Deepesh Nagarajan
NRNatasha Roy
Natasha Roy
OKOmkar Kulkarni
Omkar Kulkarni
NNNeha Nanajkar
Neha Nanajkar
ADAkshay Datey
Akshay Datey
NCNagasuma Chandra
Nagasuma Chandra
Drug resistance is a public health concern that threatens to undermine decades of medical progress. ESKAPE pathogens cause most nosocomial infections, and are frequently resistant to carbapenem antibiotics, usually leaving tigecycline and colistin as the last treatment options. However, increasing tigecycline resistance and colistin’s nephrotoxicity severely restrict use of these antibiotics. We have designed antimicrobial peptides using a maximum common subgraph approach. Our best peptide (Ω76) displayed high efficacy against carbapenem and tigecycline-resistant Acinetobacter baumannii in mice. Mice treated with repeated sublethal doses of Ω76 displayed no signs of chronic toxicity. Sublethal Ω76 doses co-administered alongside sublethal colistin doses displayed no additive toxicity. These results indicate that Ω76 can potentially supplement or replace colistin, especially where nephrotoxicity is a concern. To our knowledge, no other existing antibiotics occupy this clinical niche. Mechanistically, Ω76 adopts an α-helical structure in membranes, causing rapid membrane disruption, leakage, and bacterial death.

1 September 2005 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
GKGanesan Senthil Kumar
Ganesan Senthil Kumar
PRPalanisamy Ramasamy
Palanisamy Ramasamy
SSSujit K. Sikdar
Sujit K. Sikdar
SSSiddhartha P. Sarma
Siddhartha P. Sarma
A high yielding fusion protein system based on the protein cytochrome b(5) has been used for the production of novel 13-residue acyclic conopeptide. This peptide, Mo1659, can be liberated from the carrier protein using CNBr cleavage and subsequent purification using RP-HPLC methods. The yield of isotopically enriched peptides is high, ranging from 3 to 4mg of purified peptide from a 500ml culture, indicating that this system can be widely used for peptide production. Biosynthetic Mo1659 is active on non-inactivating K(+) channel much like the natural Mo1659, despite the absence of C-terminal amidation. Heteronuclear NMR studies show that the peptide exists in a conformational equilibrium involving proline-10. To our knowledge this is the first report of the production of an isotopically (15)N/(13)C-enriched conopeptide.

11 August 2017 in Biochemistry
Verified
Journal Article
Closed access
SBSwati Balakrishnan
Swati Balakrishnan
SSSiddhartha P. Sarma
Siddhartha P. Sarma



21 January 2011 in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
Verified
Journal Article
Closed access
GKG. Senthil Kumar
G. Senthil Kumar
SUSanjeev Upadhyay
Sanjeev Upadhyay
MMM.K. Mathew
M.K. Mathew
SSSiddhartha P. Sarma
Siddhartha P. Sarma